3,589 Merck & Co., Inc. $MRK Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 1.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 329,146 shares of the company’s stock after selling 3,589 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Merck & Co., Inc. were worth $47,828,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Curry Webb Wealth Management LLC bought a new stake in Merck & Co., Inc. during the third quarter worth $29,000. Horizons Wealth Management acquired a new stake in Merck & Co., Inc. in the third quarter valued at $30,000. Bullseye Investment Management LLC acquired a new stake in Merck & Co., Inc. in the second quarter valued at $27,000. Graney & King LLC lifted its stake in Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after acquiring an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC bought a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $41,000. 76.07% of the stock is owned by institutional investors.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
• Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
• Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
• Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock worth $29,977,783 in the last ninety days. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Price Performance

MRK stock opened at $145.25 on Monday. The stock has a market cap of $358.35 billion, a price-to-earnings ratio of 116.20, a P/E/G ratio of 6.74 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company has a 50 day simple moving average of $146.98 and a 200 day simple moving average of $130.24. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts anticipate that Merck & Co., Inc. will post 2.64 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MRK. Royal Bank Of Canada dropped their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating on the stock in a report on Monday, October 12th. HSBC lifted their price target on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Rothschild & Co Redburn lifted their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Argus boosted their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Finally, Guggenheim upped their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Seventeen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus target price of $151.92.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.